Search results
Results from the WOW.Com Content Network
Scleritis can be classified as anterior scleritis and posterior scleritis. Anterior scleritis is the most common variety, accounting for about 98% of the cases. It is of two types : Non-necrotising and necrotising. Non-necrotising scleritis is the most common, and is further classified into diffuse and nodular type based on morphology.
Episcleritis is a benign, self-limiting condition, meaning patients recover without any treatment. Most cases of episcleritis resolve within 7–10 days. [2] The nodular type is more aggressive and takes longer to resolve. [2] Although rare, some cases may progress to scleritis. [13]
Diagnosis and management of dogs with degenerative myelopathy: A survey of neurologists and rehabilitation professionals. J Vet Intern Med. 2023 Sep-Oct;37(5):1815-1820. doi: 10.1111/jvim.16829 ...
Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...
Most of the other contraindications are avoiding cases where a potential side effect exacerbates a pre-existing condition: for example, because oclacitinib can cause lumps or tumors, it should not be used in dogs with cancer or a history of it; [15] because it is an immune system suppressant, it should not be used in dogs with serious infections.
A dog with degenerative myelopathy often stands with its legs close together and may not correct an unusual foot position due to a lack of conscious proprioception. Canine degenerative myelopathy, also known as chronic degenerative radiculomyelopathy, is an incurable, progressive disease of the canine spinal cord that is similar in many ways to amyotrophic lateral sclerosis (ALS).
Therefore, it is of special significance to the selective immunosuppressive treatment, and research has been focused on the development of effective and safe anti-IL-2 antibodies. By the use of recombinant gene technology , the mouse anti-Tac antibodies have been modified, leading to the presentation of two chimeric mouse/human anti-Tac ...
Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]